Non Small Cell Lung Cancer, brain metastases, MRI, 18FDG-PET-CT with contrast enhanced CT brain niet kleincellig longkanker, hersenmetastasen, MRI, 18FDG-PET-CT met diagnostische CT van het brein
Conditions
Interventions
None, observational.
Sponsors
MUMC+
Eligibility
Inclusion criteria
Inclusion criteria: 1. Pathology proven NSCLC; 2. UICC stage III; 3. Eligible for therapy with curative intent; 4. Staging based on 18FDG-PET-CE-CT; 5. No contra-indication for MRI or CE-CT; 6. MRI within 3 weeks after 18FDG-PET-CE-CT.
Exclusion criteria
Exclusion criteria: 1. Other malignancy that is not controlled or that was diagnosed less than 2 years before enrolment in this study, except skin cancer or cervical cancer in situ; 2. Contra-indication for MRI or CE-CT; 3. Mixed histologies such as combined small cell and non-small cell lung cancer; 4. Recurrent disease only if not eligible for therapy with curative intent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with additional brain metastasis found on MRI after negative CE-CT. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Asymptomatic brain metastasis found on 18FDG-PET-CE-CT in otherwise stage III NSCLC patients; 2. Cost analysis; 3. Number of patients with symptomatic brain metastasis within a year after an initially negative MRI and time to symptomatic brain metastasis. | — |
Contacts
Public ContactAnne-Marie C. Dingemans
University Hospital Maastricht P.O.Box 5800
Outcome results
None listed